| Date | Event | Impact |
|---|---|---|
| 15 Jun 2026 | Stock +13.06% on ~12.6x relative volume (~18.25M shares) — episodic-pivot style breakout from base | Positive |
| 4 May 2026 | FY26 audited results: Rev ₹8,286 Cr (+14%), EBITDA ₹1,172 Cr, PAT ₹419 Cr (+27%); Re 1 (20%) dividend declared | Positive |
| FY26 capex | ~₹1,125 Cr deployed; CWIP rose to ₹2,030 Cr — Zone 4, Augene & RE Aarti JV in flight | Watch |
| Guidance | Management FY28 EBITDA target set at ₹1,800–2,200 Cr; ₹300–450 Cr pilot to commercialise new products | Positive |
| H1 FY27 | DCA downstream project (Superform JV) expected to commission; Re Aarti plastics chemical-recycling JV targeted CY26 | Positive |
| Balance sheet | Borrowings up to ₹4,966 Cr (D/E 0.83x); cash & equivalents rose to ~₹583 Cr from ₹199 Cr | Watch |
Aarti Industries (AIL), the flagship of the Aarti Group, is one of India's leading diversified specialty chemicals manufacturers, with a globally significant franchise in benzene-based chemistry. Incorporated in 1984 and headquartered in Mumbai, it operates a vertically integrated cluster of plants across Vapi, Jhagadia, Dahej, Kutch (Gujarat) and Tarapur (Maharashtra), serving agrochemicals, polymers & additives, pharma intermediates, dyes & pigments, fuel additives and other downstream applications. AIL is among the global top-3/4 in several Nitro-Chloro-Benzene (NCB) chain products and supplies ~40% of India's benzene-derivative demand.
Its edge is backward-integrated, process-chemistry depth built over four decades: long-term contracts with global innovators, recurring multi-year supply agreements, and the ability to scale niche molecules. The current moment matters because the post-2022 down-cycle (China dumping, destocking, weak agrochem demand) appears to be bottoming — FY26 shows the first clean revenue + PAT recovery, while a large capex book (Zone-4, Augene, value-added JVs) is set to convert into earnings from FY27.
World-scale NCB chain, captive power & backward integration → structural cost lead. Strong
Long-gestation customer qualification, multi-year contracts, complex process know-how. Strong
Dominant share in niche molecules limits new-entrant economics. Moderate
AIL runs dedicated R&D & pilot facilities; FY27 plans a ₹300–450 Cr pilot project to commercialise new molecules. Value-added pipeline: DCA downstream (Superform JV, ~H1FY27 commissioning), chemical recycling of plastics via Re Aarti JV (CY26), plus Zone-4 & Augene capacity. New chemistries (fluorination, agrochem actives, energy/EV-linked intermediates) are the multi-year optionality.
| Project / Platform | Stage | Expected | Significance |
|---|---|---|---|
| DCA downstream (Superform JV) | Construction | H1 FY27 | Value-added forward integration |
| Re Aarti — plastics chem-recycling | Construction | CY26 | New circular-economy vertical |
| Zone-4 & Augene expansion | Capex in flight | FY27–28 | Volume + mix uplift |
| New-molecule pilot (₹300–450 Cr) | Pilot | FY27+ | Future specialty optionality |
~12+ multi-product sites across Gujarat & Maharashtra; flexible batch + continuous process chemistry.
Backward into key feedstocks; captive utilities; ability to swing product mix toward higher-value derivatives.
Multi-year supply agreements with global agrochem/pharma innovators provide volume visibility.
Shift revenue mix toward value-added & specialty from commoditised intermediates — margin expansion lever.
Monetise the capex cycle: convert ₹2,030 Cr CWIP into revenue, targeting FY28 EBITDA ₹1,800–2,200 Cr.
New verticals via JVs (DCA/Superform, Re Aarti recycling) & sustainability/ESG-led chemistries.
India's specialty chemicals industry (~US$32–40bn) is projected to compound low-double-digits as global supply chains diversify away from China ("China+1") and domestic agrochem/pharma demand normalises. AIL is positioned as a scaled, integrated benzene-chemistry supplier able to capture both import-substitution and export-relocation flows.
Cyclical recovery: volume normalisation, destocking ending, gradual margin repair off a 14% OPM base.
Capex commissioning (Zone-4, JVs) drives the FY28 EBITDA step-up toward ₹1,800–2,200 Cr.
China+1 structural relocation, new chemistries (fluorination, recycling) and operating leverage on a larger asset base.
| Project | Location / Type | Status | Revenue impact |
|---|---|---|---|
| Zone-4 expansion | Gujarat · specialty | In progress | FY27–28 ramp |
| Augene project | Value-added derivatives | In progress | FY27 onward |
| DCA downstream (Superform JV) | Forward integration | Commissioning H1FY27 | Near-term uplift |
| Re Aarti — plastics recycling JV | New vertical | CY26 | Optional / nascent |
| New-molecule pilot | ₹300–450 Cr | Pilot | FY27+ optionality |
| Scheme / Change | Relevance | Direction |
|---|---|---|
| China+1 / global supply diversification | Export relocation tailwind for integrated Indian chem | Positive |
| Anti-dumping duties on select Chinese chemicals | Protects domestic intermediate pricing | Positive |
| Tighter environmental / pollution norms (CPCB) | Compliance capex; favours scaled, compliant players | Mixed |
| REACH / global agrochem regulation | Demand timing for active-ingredient intermediates | Mixed |
| Crude / benzene feedstock & FX | Input cost & export realisation volatility | Watch |
Specialty-chemicals desks at large domestic brokerages (Motilal Oswal, Kotak, ICICI Securities, Nuvama, among others) cover AIL. Common threads in public commentary:
- FY26 marks a cyclical bottoming; consensus models a multi-year recovery in revenue toward ₹9,000–10,000 Cr+ as capex commissions.
- Margin recovery is the swing variable — street watches OPM moving back toward 16–18% vs the 14% FY26 base.
- The management FY28 EBITDA target of ₹1,800–2,200 Cr is the key anchor for forward estimates.
- Debate centres on valuation: ~43x trailing P/E embeds a strong recovery already.
| Item | FY26 | FY25 |
|---|---|---|
| Equity Capital | 181 | 181 |
| Reserves | 5,774 | 5,424 |
| Borrowings | 4,966 | 3,848 |
| Fixed Assets | 6,556 | 6,377 |
| CWIP | 2,030 | 1,454 |
| Cash & equiv. | ~583 | 199 |
| Total Assets | 13,299 | 11,114 |
| Year | CFO | CFO/OP | FCF |
|---|---|---|---|
| FY26 | 775 | 67% | -346 |
| FY25 | 1,242 | 123% | -137 |
| FY24 | 1,210 | 132% | -96 |
| FY23 | 1,319 | 129% | -8 |
Rose 39→62 days (debtor 58→81 on standalone). Watch — could signal looser credit in recovery.
126→118, stable / improving vs revenue growth.
Multi-year CFO well above PAT — earnings backed by cash.
Historically negligible (verify latest filing).
Negative/low headline tax (-15% FY26) from deferred tax & incentives — Screener flags "tax seems low".
No auditor change or RPT red flag noted.
| Quarter | Rev ₹Cr | QoQ | YoY | EBITDA | OPM | PAT | EPS |
|---|---|---|---|---|---|---|---|
| Mar-26 | 2,205 | -5% | +13% | 341 | 15% | 137 | 3.78 |
| Dec-25 | 2,318 | +10% | +26% | 321 | 14% | 133 | 3.67 |
| Sep-25 | 2,100 | +25% | +29% | 291 | 14% | 106 | 2.92 |
| Jun-25 | 1,675 | -14% | -10% | 212 | 13% | 43 | 1.19 |
| Mar-25 | 1,949 | +6% | +10% | 262 | 13% | 96 | 2.65 |
| Dec-24 | 1,843 | +13% | +6% | 231 | 13% | 46 | 1.27 |
| Multiple | Current | ~3Y Median | Read |
|---|---|---|---|
| P/E | 43.5x | ~40x | Slight premium — earnings depressed |
| P/B | 3.0x | ~3.5x | Below mean |
| EV/EBITDA | ~17.4x | ~16x | Modest premium |
| Company | Mkt Cap ₹Cr | Rev TTM* | P/E | ROCE% | ROE% |
|---|---|---|---|---|---|
| Aarti Industries ★ | 18,065 | 8,286 | 43.5 | 6.8 | 7.2 |
| SRF | 80,642 | ~14,700 | 45.0 | 15.9 | 14.8 |
| Navin Fluorine | 37,380 | ~2,800 | 75.8 | 21.3 | 16.0 |
| Deepak Nitrite | 22,733 | ~8,300 | 115 | 7.4 | 6.2 |
AIL is promoter-led (Gala/Shah founding families; promoter holding ~42%). Long operating track record (40+ years) with credible scale-up through cycles. However, the 2023–25 down-cycle exposed earnings cyclicality and the gap between aspirational targets and delivered ROCE.
| Period | Guidance theme | Actual | Read |
|---|---|---|---|
| FY22 peak | Strong specialty growth | Record PAT ₹1,186 Cr (one-off cycle) | Hit (cyclical) |
| FY23–24 | Recovery "soon"; capex on track | Earnings fell sharply (China dumping, destock) | Miss |
| FY25 | Gradual normalisation | PAT ₹331 Cr — bottomed | Partial |
| FY26 | Volume-led recovery | Rev +14%, PAT +27% — delivered | Hit |
Low ROCE / profitability
ROCE ~7% and ROE ~7% are well below cost of capital and the 18–22% earned pre-2023. A rising asset base must earn its keep.
Capex execution & leverage
D/E up to 0.83x; ₹2,030 Cr CWIP. Delayed/under-utilised commissioning would depress returns and strain cash.
China dumping / pricing
Chinese oversupply in benzene derivatives can compress spreads and stall the recovery, as seen in FY23–25.
Valuation
~43x trailing P/E embeds a strong recovery; disappointment vs FY28 target risks de-rating.
End-market / agrochem demand
Global agrochem destocking & weak demand directly hit intermediate volumes.
Feedstock & FX volatility
Benzene/crude swings and INR moves affect spreads and export realisations.
Receivable creep
Debtor days rising (39→62) — monitor working-capital discipline in the upcycle.
Promoter / governance
Promoter-led; no pledge or RPT red flags noted.
| Milestone | Watch for | Timeline | Why it matters |
|---|---|---|---|
| OPM back to 16%+ | Quarterly EBITDA margin | FY27 | Confirms margin normalisation vs 14% base |
| DCA (Superform JV) commissioning | Plant start & ramp | H1 FY27 | First value-added capex turning to revenue |
| Re Aarti recycling JV start | Commissioning | CY26 | New vertical optionality |
| EBITDA run-rate vs FY28 target | ₹1,800–2,200 Cr glidepath | FY27–28 | Validates the core thesis |
| ROCE trend | Annual ROCE moving toward 12%+ | FY27–28 | The single most important quality metric |
| Debtor days & D/E | Working capital + leverage discipline | Each quarter | Balance-sheet health during capex |
- Promoter ~42.1% — stable, no pledge flagged.
- FII ~7.4% — edged up over recent quarters off low levels.
- DII ~9–20% (LIC & domestic MFs hold positions); public/retail ~30%.
- Free float ~57% (per TradingView) — liquid mid-cap.
- No promoter selling or pledge red flags noted.
Assumption: recovery stalls, China dumping persists, margins stay ~13–14%, capex under-utilised. EBITDA flat ~₹1,150 Cr; multiple de-rates to ~13x.
1Y ref: ₹330–360 · 2Y: ₹300–360 · 3Y: ₹310–390
Assumption: steady recovery, margins to ~15–16%, capex commissions on schedule. EBITDA ~₹1,450–1,600 Cr by FY28; multiple ~16–17x.
1Y ref: ₹470–520 · 2Y: ₹520–600 · 3Y: ₹600–700
Assumption: FY28 EBITDA target (₹1,800–2,200 Cr) delivered, margins 17–18%, sector re-rates. Multiple ~18–19x.
1Y ref: ₹540–600 · 2Y: ₹650–780 · 3Y: ₹820–1,000+
AIL is emerging from a long Stage-1/early Stage-2 base. The 15-Jun session printed a +13% expansion-range breakout on ~12.6x relative volume (~18.25M shares) — classic episodic-pivot behaviour following the FY26 results and recovery narrative. Price has reclaimed the rising 50-day region after a multi-month consolidation between roughly ₹428 and ₹500. Weekly trend is turning up (higher low at ₹428 vs prior ₹338), while the longer downtrend line from the 2024 ₹766 peak is being challenged.
- Volume: breakout day RVOL ~12.6x with the largest up-volume bar on the chart — strong demand footprint (Highest Volume "Bullish", Largest Spread "Bullish").
- Moving averages: price (₹498) back above the fast/slow EMA cluster (~₹458–462); weekly MA score 0.80 (bullish alignment building).
- RS: +5.59% vs RS-MA, RS Days 22 — strongly outperforming CNX500.
- RSI (weekly): rising into the 60s, room before overbought; oscillator score modestly positive (0.27).
- 52-week position: CMP ₹498 vs 52W ₹338–₹523 — near the top of the 1Y range, ~3% below the 52W high.
AIL is the technical leader of its specialty-chem peer set on the weighted TA ranking, having just outperformed on the breakout:
| Ticker | Weighted TA | Signal |
|---|---|---|
| AARTIIND ★ | 0.27 | Buy |
| NAVINFLUOR | 0.20 | Buy |
| SRF | 0.07 | Neutral |
| DEEPAKNTR | -0.03 | Neutral |
| VINATIORGA | -0.05 | Neutral |
- Daily/weekly close holding above ₹500 with volume > 20-day avg.
- Decisive close above ₹523 (52W high) → opens ₹557–597.
- Daily TA flipping from Neutral to Buy.
- Loss of ₹461 EMA then ₹428 base low on volume.
- Failed breakout / reversal back into the ₹428–460 range.
- Break below ₹398 → trend damage.
Aarti Industries is a scaled, backward-integrated benzene-chemistry leader emerging from a brutal 2023–25 specialty-chemicals down-cycle. FY26 delivered the first clean recovery (revenue +14%, PAT +27%), and a large capex book — Zone-4, Augene, and value-added JVs — is set to commission from FY27, underpinning management's FY28 EBITDA target of ₹1,800–2,200 Cr (vs ₹1,172 Cr in FY26). The technical picture has just inflected: a +13% volume breakout from a multi-month base, weekly TA "Strong Buy", and sector-leading relative strength. The tension is that profitability is still poor (ROCE/ROE ~7%) and the ~43x trailing multiple already discounts a recovery, so the thesis rests on capex execution and margin normalisation actually arriving.